Anemia
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and IgG4-related disease.
The oral agent exhibited promising hemoglobin response performance and safety in this stage of an ongoing phase 2/3 study.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
A prospective study involved ultrasound imaging of patients' carotid arteries to evaluate for structural changes.
Further study is needed to determine if a particular eGFR biomarker best predicts cardiovascular risks.
Study data show the VAS-101 gel formulation helps preserve therapeutic efficacy and extend useful longevity of stored RBCs.
A systematic review found IV administration to have fewer postoperative complications and better quality of life.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.